Albemarle (NYSE:ALB – Get Free Report) is anticipated to post its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect Albemarle to post earnings of $3.20 per share and revenue of $1.6069 billion for the quarter. Investors may visit the the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:00 AM ET.
Albemarle (NYSE:ALB – Get Free Report) last posted its earnings results on Wednesday, May 6th. The specialty chemicals company reported $2.95 EPS for the quarter, beating analysts’ consensus estimates of $1.24 by $1.71. The firm had revenue of $1.43 billion for the quarter, compared to analysts’ expectations of $1.34 billion. Albemarle had a positive return on equity of 5.22% and a negative net margin of 5.00%.The company’s quarterly revenue was up 32.7% on a year-over-year basis. During the same period last year, the firm earned ($0.18) EPS. On average, analysts expect Albemarle to post $13 EPS for the current fiscal year and $12 EPS for the next fiscal year.
Albemarle Stock Performance
NYSE ALB opened at $117.46 on Monday. The stock has a market capitalization of $13.85 billion, a price-to-earnings ratio of -34.45 and a beta of 1.33. Albemarle has a twelve month low of $64.95 and a twelve month high of $221.00. The company has a current ratio of 2.07, a quick ratio of 1.21 and a debt-to-equity ratio of 0.23. The stock has a 50-day moving average of $142.86 and a 200 day moving average of $165.76.
Albemarle Increases Dividend
Wall Street Analysts Forecast Growth
ALB has been the subject of a number of recent analyst reports. UBS Group boosted their price objective on Albemarle from $230.00 to $264.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Vertical Research raised shares of Albemarle from a “hold” rating to a “buy” rating and set a $224.00 price target on the stock in a research note on Tuesday, May 26th. Jefferies Financial Group cut their price target on shares of Albemarle from $244.00 to $211.00 and set a “buy” rating for the company in a report on Tuesday, June 30th. Truist Financial reduced their price objective on shares of Albemarle from $260.00 to $245.00 and set a “buy” rating for the company in a research report on Monday, July 20th. Finally, Deutsche Bank Aktiengesellschaft increased their price objective on shares of Albemarle from $210.00 to $250.00 and gave the company a “buy” rating in a report on Tuesday, May 12th. Fifteen equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $199.22.
Read Our Latest Analysis on Albemarle
Insider Buying and Selling
In other Albemarle news, CEO J Kent Masters sold 16,393 shares of the stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $183.72, for a total value of $3,011,721.96. Following the completion of the sale, the chief executive officer owned 87,519 shares in the company, valued at approximately $16,078,990.68. This represents a 15.78% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.42% of the company’s stock.
Institutional Investors Weigh In On Albemarle
Large investors have recently made changes to their positions in the stock. AQR Capital Management LLC grew its position in Albemarle by 22,047.4% in the second quarter. AQR Capital Management LLC now owns 713,812 shares of the specialty chemicals company’s stock worth $44,613,000 after acquiring an additional 710,589 shares during the period. Samlyn Capital LLC purchased a new stake in Albemarle in the third quarter valued at $47,088,000. Caisse de depot et placement du Quebec purchased a new stake in Albemarle in the third quarter valued at $41,239,000. Worldquant Millennium Advisors LLC lifted its stake in shares of Albemarle by 60.9% in the 2nd quarter. Worldquant Millennium Advisors LLC now owns 784,083 shares of the specialty chemicals company’s stock valued at $49,138,000 after purchasing an additional 296,861 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its stake in shares of Albemarle by 265.3% in the 4th quarter. The Manufacturers Life Insurance Company now owns 320,498 shares of the specialty chemicals company’s stock valued at $45,331,000 after purchasing an additional 232,764 shares during the last quarter. 92.87% of the stock is currently owned by hedge funds and other institutional investors.
Albemarle Company Profile
Albemarle Corporation is a leading global specialty chemicals company primarily engaged in the production and distribution of lithium, bromine, and catalysts. Its lithium segment supplies key components used in rechargeable batteries for electric vehicles, portable electronics, and grid storage systems. The company’s bromine specialty products serve a wide range of industries, including oil and gas drilling fluids, fire safety solutions, and water treatment. In its catalysts division, Albemarle provides products for petroleum refining, chemical processing and emissions control.
Founded in 1994 as a spin-off from Ethyl Corporation, Albemarle has grown through strategic acquisitions and capacity expansions to become one of the world’s foremost chemical producers.
Read More
- Five stocks we like better than Albemarle
- 3 Fixed-Income ETFs Show Why Yield Is Only Part of the Income Story
- AbbVie Quietly Solved Its Biggest Problem—Now What?
- Rio Tinto’s Results Make the Case for Looking Beyond Tech in the AI Trade
- Strategy’s Structural Strength: Hidden in a $8 Billion Illusion
Receive News & Ratings for Albemarle Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albemarle and related companies with MarketBeat.com's FREE daily email newsletter.
